Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

一项针对携带野生型 EGFR 的 IIIB/IV 期非小细胞肺癌患者的 II 期临床研究，评估阿法替尼作为三线治疗方案的疗效。